Mec-HFS-TCNCT07911891
Oral Mecobalamin for TKI-Associated Hand-Foot Syndrome in Advanced Thyroid Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Proportion of patients with HFS grade improvement ≥1 at week 8
Timeframe: Week 8
Secondary (4)
Change in VAS pain score from baseline to week 8
Change in KPS performance status from baseline to week 8
Proportion of patients requiring TKI dose adjustment due to HFS
Incidence of adverse events related to study medication
Arms and interventions
Control GroupPlacebo comparator
Patients receive routine skin care with topical urea ointment 3 times daily for 8 weeks.
Mecobalamin GroupExperimental
Patients receive routine skin care plus oral mecobalamin 0.5 mg 3 times daily for 8 weeks.
Drugs: Mecobalamin
Other: Urea Ointment
Sites
1 site in 1 country
- West China Hospital, Sichuan UniversityChengdu, Sichuan, China